. Author manuscript; available in PMC: 2012 Sep 24.

Published in final edited form as: Surg Oncol Clin N Am. 2009 Oct;18(4):637–645. doi: 10.1016/j.soc.2009.07.003

Table 2.

Adapted from Abdel-Rahman et al [13]

	Type X N=18 tumors	Lynch N=31 tumors	Sporadic from literature	P-value for Type X vs Lynch	P-value for Type X vs Sporadic
Nuclear beta-catenin	39%	81%	95%	0.005	0.000005
CTNNB1 mutations	0%	29%	6%	0.007	NS
CDX2 alteration: decreased protein	11%	6%	16%	NS	NS
KRAS exon 2 mutations	17%	26%	30%	NS	NS
BRAF V600E	4%	0%	3%	NS	NS
P53 protein stabilization	44%	13%	52%	0.04	NS
TP53 mutation	26%	13%	52%	NS	0.01
Chromosomal instability by CGH	44%	Not done	79%		0.00006

NS=not significant; CGH= comparative genomic hybridization